Stocks · News reference

Nasus Pharma Announces CFO Eyal Rubin To Depart September 18; Appoints Oren Elmaliach As Interim CFO

Aug 19, 2026, 11:06 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 17, 2026, 12:15 PMBenzinga Newsdesk
Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate
Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the
Read original at benzinga
NSRX
Globenewswire IncJul 28, 2026, 11:30 AMNa
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
Nasus Pharma Ltd. (NYSE: NSRX) announced the appointment of Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026. O'Grady, a pharmaceutical industry veteran with 35 years of experience and former CEO of Teva USA, will lead the company's growth strategy with focus on commercializing NS002, an intranasal epinephrine treatment for anaphylaxis targeting a $2 billion market opportunity. He succeeds Dan Teleman in the leadership transition.
Read original at globenewswire-inc
NSRX
BenzingaJul 28, 2026, 11:33 AMBenzinga Newsdesk
Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the
Read original at benzinga
NSRX